Sección de Dermatología, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Am J Clin Dermatol. 2014 Feb;15 Suppl 1:S5-16. doi: 10.1007/s40257-013-0054-4.
Psoriasis is a disabling chronic inflammatory condition of the skin and joints that typically requires long-term treatment. Recommended treatments for psoriasis include a wide range of topical and systemic options, from topical agents and targeted phototherapy for mild psoriasis to traditional systemic agents such as methotrexate, cyclosporine and acitretin for more serious disease. The introduction of targeted biological agents such as T-cell-modulating agents, tumor necrosis factor α (TNFα) antagonists and interleukin (IL)-12 and IL-23 inhibitors has provided new choices for the management of psoriasis and psoriatic arthritis that may offer better long-term efficacy and tolerability than traditional approaches. Most biological agents are administered by subcutaneous injection. Infliximab, a TNFα antagonist, is the only biological agent approved for psoriasis that is administered by intravenous infusion, in the setting of hospital-based or specialized infusion center-based clinics. Infliximab allows weight-based dosing and may offer more rapid disease control than other biological agents, with significant improvements seen as early as 1 week after treatment initiation. This article gives an overview of psoriasis management, focusing on clinic-based infusion therapy with infliximab.
银屑病是一种影响皮肤和关节的慢性炎症性疾病，通常需要长期治疗。银屑病的推荐治疗方法包括广泛的局部和全身治疗方案，从轻度银屑病的局部药物和靶向光疗，到更严重疾病的传统全身药物如甲氨蝶呤、环孢素和阿维 A 等。靶向生物制剂的引入，如 T 细胞调节剂、肿瘤坏死因子-α（TNFα）拮抗剂和白细胞介素（IL）-12 和 IL-23 抑制剂，为银屑病和银屑病关节炎的治疗提供了新的选择，它们可能比传统方法具有更好的长期疗效和耐受性。大多数生物制剂通过皮下注射给药。英夫利昔单抗是唯一一种经静脉输注给药的 TNFα 拮抗剂，获批用于银屑病治疗，在医院或专门的输液中心诊所中使用。英夫利昔单抗可以根据体重给药，与其他生物制剂相比，可能更快地控制疾病，在治疗开始后 1 周即可看到显著改善。本文概述了银屑病的管理，重点介绍了英夫利昔单抗的基于诊所的输液治疗。
